Incannex Healthcare

IXHL

Market cap $63.6M

MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.

Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days

MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundation's Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026.

MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors. At current trading levels, Incannex's market capitalization is approximately $46 million — representing a significant disconnect to the Company's $75 million cash position and resulting in a negative enterprise value.

MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company received written confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement after its common stock maintained a closing bid price of $1.00 per share or greater for eleven consecutive business days, from February 27 through March 13, 2026.

Incannex Healthcare Limited (NASDAQ: IXHL) shares are tumbling on Thursday as the company announced a registered direct offering of $10 million.

NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the “Company") a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced that it has entered into a securities purchase agreement with healthcare-dedicated institutional investors for the issuance and sale of 2,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and accompanying common warrants to purchase up to an aggregate of 2,000,000 shares of its common stock at a combined purchase price of $5.00 per share and accompanying common warrants. The financing is expected to generate aggregate gross proceeds of approximately $10.0 million at closing. If the common warrants issued in the financing are exercised in full for cash, the Company would receive up to an additional $13.0 million in gross proceeds, for total potential gross proceeds of approximately $23.0 million. The offering is expected to close on or about March 13, 2026, subject to the satisfaction of customary closing conditions.

Incannex's common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026 Incannex's common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026

Dallas, Texas--(Newsfile Corp. - February 18, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses.

MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD.